Jazz Pharmaceuticals (JAZZ) and Azur Pharma Combine to Create Jazz Pharmaceuticals plc

Jazz Pharmaceuticals (JAZZ) stock is halted but will open back for trading in a little bit. The following news will effect the stock price today
 

Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc
 

Jazz Pharmaceuticals plc (Nasdaq: JAZZ - News) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc. The two companies have combined to create Jazz Pharmaceuticals plc, a specialty biopharmaceutical company based in Dublin, Ireland. Following the closing, Jazz Pharmaceuticals plc has approximately 60 million outstanding ordinary shares on a fully diluted basis.
 

"As Jazz Pharmaceuticals plc, we are a growing, profitable specialty biopharmaceutical company with a diverse portfolio of products in the central nervous system and women's health areas," said Bruce Cozadd, chairman and chief executive officer at Jazz Pharmaceuticals. "We now have a strengthened management team, a broader commercial organization and an efficient platform for further growth, with resources to build our product portfolio and a future pipeline."
Jazz Pharmaceuticals has approximately 430 employees, including a commercial organization focused around four key areas: narcolepsy, severe chronic pain, psychiatry and a diversified portfolio of women's health products. In addition to its headquarters in Dublin, Ireland, the company has offices in Palo Alto, California and Philadelphia, Pennsylvania.
 

http://www.jazzpharmaceuticals.com/